Castrate Resistant Prostate Cancer (CRPC)
Conditions
Brief summary
This is a Phase I, non-randomized, multiple-dose, 3+3 dose-escalation study of the safety, pharmacokinetics, biomarkers, preliminary efficacy and patient-reported outcomes of therapeutic vaccine, BPX-101 (formerly BP-GMAX-CD1), plus activating agent, AP1903, in patients with castrate resistant prostate cancer.
Detailed description
Patients will be screened within 6 weeks prior to Week 1. A total of 3 cohorts, consisting of 3 to 6 patients each, are planned to receive five to eight intradermal (ID) injections totaling 1 mL up to 1.6mL of BPX-101 at 3 doses levels for an initial 6 doses.
Interventions
BIOLOGICALBPX-101
Vaccine
DRUGAP1903
Activating agent, infusion
Sponsors
M.D. Anderson Cancer Center
The University of Texas Health Science Center, Houston
Memorial Hermann Hospital
Baylor College of Medicine
Bellicum Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males ≥ 18 years of age 2. Histological diagnosis of adenocarcinoma of the prostate 3. Documented evidence of distant metastasis of disease 4. No more than 1 prior chemotherapeutic, biologic or combination treatment regimen (including vitamin D analogues) for CRPC. If previously treated, patients must be recovered from all toxicities prior to entry into the study. 5. Patients must have current or historical evidence of disease progression concomitant with surgical (orchiectomy) or medical castration (LHRH analogue); anti-androgen withdrawal (4 weeks for flutamide and 6 weeks for nilutamide or bicalutamide) is necessary only for patients on antiandrogens and a duration of response to antiandrogens \> 3months; 6. Testosterone \< 50 ng/dL achieved via medical or surgical castration. Patients receiving medical castration therapy must continue such therapy throughout the study. 7. Adequate hematologic, renal and liver function: 8. Negative serology tests for human immunodeficiency virus (HIV-1 and 2), human T-cell lymphotropic virus (HTLV-1), hepatitis B surface antigen (HBsAg) and hepatitis C (HCV) 9. Karnofsky Performance Score (KPS) ≥ 70% 10. Life expectancy \> 6 months 11. Written informed consent obtained prior to the initiation of study procedures
Exclusion criteria
1. The presence of brain metastases, pleural effusions or ascites 2. Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography \> 50%), or spinal cord compression 3. A history of stage III or greater cancer, excluding prostate cancer. Basal or squamous cell skin cancers must have been adequately treated and the patient must be disease-free at the time of registration. Patients with a history of stage I or II other cancers must have been adequately treated and been disease-free for 3 years at the time of registration. 4. More than 1 prior chemotherapy, biologic or combination treatment regimen (including vitamin D analogues) for CRPC 5. Any treatment with radiopharmaceuticals, e.g. Strontium-89 and Samarium-153 6. Ketoconazole or antiandrogens (flutamide, nilutamide, bicalutamide) within 2 weeks prior to registration. Patients who demonstrate an anti-androgen withdrawal response, defined as a \> 25% drop in PSA within 4 weeks (flutamide) or 6 weeks (nilutamide, bicalutamide) of stopping a non-steroidal anti-androgen, are not eligible until the PSA rises above the nadir observed after anti-androgen withdrawal. 7. Initiation of bisphosphonate therapy within 28 days prior to registration. Patients taking bisphosphonates should not have their dosing regimen altered unless medically warranted. 8. A requirement for systemic steroid or other immunosuppressive therapy for any reason. 9. Treatment with any of the following medications or interventions \< 28 days prior to Screening 10. Treatment with any investigational vaccine within 2 years prior to Screening, or treatment with any other investigational product within 28 days prior to Screening 11. Any antibiotic therapy or infection within 1 week prior to Screening, including unexplained fever (temperature ≥ 100.5F or 38.1C) 12. History of autoimmune disease 13. Serious ongoing chronic or acute illness 14. Any medical intervention or other condition which, in the opinion of the Principal Investigator and/or the Bellicum Medical Monitor, could compromise adherence with study requirements Other Criteria Apply however are not listed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose of BPX-101 and AP1903 | 1 Year | To determine the maximum tolerated dose (MTD) of BPX-101 and AP1903 when administered 24 hours apart |
| Safety and tolerability of BPX-101 and AP1903 | 1 Year | To determine other measures of safety and tolerability of BPX-101 and AP1903 when administered 24 hours apart to patients with castrate resistant prostate cancer (CRPC). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PSA response and PSA dynamics | 1 Year | To assess PSA response and PSA dynamics (change in velocity, doubling time) |
| Number of circulating tumor cells (CTC) | 1 Year | To assess reduction in the number of circulating tumor cells (CTC) |
| Pharmacokinetics of AP1903 | 1 Year | To determine the pharmacokinetics of AP1903 when administered 24 hours after BPX-101 |
| Pain medication usage | 1 Year | To assess pain medication usage |
| Preliminary efficacy of BPX-101 at the maximum tolerated dose (MTD) | 2 Years | To determine preliminary efficacy of BPX-101 at the maximum tolerated dose (MTD), based on tumor assessments using computed tomography (CT) or magnetic resonance imaging (MRI) and radionuclide bone scans |
| Cancer-related pain | 1 Year | To assess cancer-related pain |
| Immune responses and their association with clinical outcome | 2 Years | To assess immune responses and their association with clinical outcome as measured by changes in levels of interferon gamma (IFN)-producing T cells, the cytotoxic T lymphocyte (CTL) response, cytokines (IFN, IL-4, IL-10), activation markers, and other markers |
Countries
United States
Outcome results
None listed